Renni Marcos José Pereira, Cerqueira Mônica Hermida, Trugilho Ingrid de Araújo, Araujo Mario Lúcio Cordeiro, Marques Marcos Arêas, Koch Hilton Augusto
Instituto Nacional do Câncer - INCA, Divisão de Pesquisa Clínica, Rio de Janeiro, RJ, Brasil.
Instituto de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO, Rio de Janeiro, RJ, Brasil.
J Vasc Bras. 2017 Oct-Dec;16(4):308-313. doi: 10.1590/1677-5449.007817.
There is a strong relationship between venous thromboembolism and cancer. Patients with tumors have a higher incidence of thromboembolic events in their clinical evolution. The occurrence of such events is considered a negative predictive marker in this group of patients. Thus, we aim to review activation of coagulation mechanisms in this group of patients. Activation of coagulation mechanisms in cancer patients is a complex and multifactorial process, related to tumor characteristics, clinical staging, the disease’s aggressiveness, tumor sites, and additional factors caused by disease progression. New biomarkers have been under investigation over the years in the attempt to correlate them to the risk of thrombosis, aiming to develop interventions that improve the clinical evolution of these cancer patients.
静脉血栓栓塞与癌症之间存在密切关系。肿瘤患者在临床病程中发生血栓栓塞事件的几率更高。此类事件的发生被认为是这组患者的负面预测指标。因此，我们旨在综述这组患者凝血机制的激活情况。癌症患者凝血机制的激活是一个复杂的多因素过程，与肿瘤特征、临床分期、疾病侵袭性、肿瘤部位以及疾病进展导致的其他因素有关。多年来一直在研究新的生物标志物，试图将它们与血栓形成风险相关联，旨在开发改善这些癌症患者临床病程的干预措施。
